News & Insights

• Oxford Endovascular Ltd is commercialising OxiFlow™, a novel blood flow diversion device (‘stent’) for treating Intracranial Aneurysms (ICAs).
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $10m Series A funding round led by Vulpes Investment Management, a Singapore-based life sciences investor.
• This is the second OTIF investment in Oxford Endovascular to date, bringing total funds invested by the fund in the Company to £500k.

OIC portfolio company Oxehealth has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

The two rounds have been underwritten by existing shareholders, which included a commitment from the Oxford Technology & Innovations EIS Fund (OTIF) advised by OIC.

OIC investee company SpyBiotech, which is developing a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor.

OIC portfolio company Cytox launches a non-invasive genetic test enabling physicians to assess an individual’s risk of cognitive decline due to Alzheimer’s from a simple saliva sample provided from home.

Excitingly, the test can guide lifestyle interventions to potentially slow disease progression.

We’re excited to announce the launch of the first 2021 round of the Oxford Technology and Innovations EIS Fund (OTIF) advised by us and managed by Thompson Taraz!